A prototype smart ring tracks multiple metabolic biomarkers in sweat, while Amazon One Medical launches Health Insights for blood biomarker analysis. Pharmacies are also using point-of-care testing to personalize supplement recommendations.
The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
Removing olfactory groove meningioma may improve blood sugar control in diabetes patients, a JAMA Network Open study finds. Both intermittent and continuous calorie restriction also improve metabolic health in type 2 diabetes.
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
Phase 2 MINDFuL results for XPro1595 in early Alzheimer's disease were published, showing positive trends and no ARIA. FDA aligned on a phase 2b/3 registrational design. Webinar set for Feb 27, 2026.
InsideTracker's peer-reviewed PLOS Digital Health study of 20,000 users found sustained improvements across 39 blood biomarkers, including LDL, HbA1c, glucose, vitamin D, hsCRP and testosterone, linked to use of its personalized platform.
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
